

# Oryzon Genomics

Ramping up R&D activity; catalysts in 2019

Q318 company update

Pharma & biotech

The €13m (gross) private placement announced on 30 October 2018 will support Oryzon's expanding R&D programme with a total of five clinical trials now underway. Two new Phase IIa trials with iadademstat (formerly ORY-1001) are starting in acute myeloid leukaemia (AML) (ALICE trial) and small cell lung cancer (SCLC) (CLEPSIDRA trial). Results from another two Phase IIa studies with vafidemstat (formerly ORY-2001) in Alzheimer's disease (AD) patients (ETHERAL) and multiple sclerosis (MS) patients (SATEEN) are due to report results in H219. Before that, interim results from the innovative design 'basket trial' with vafidemstat in aggression control in various neuropsychiatric conditions are due in H119. Our valuation is €342m or €8.7 per share (vs €328m or €9.6 per share).

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/16	5.0	(4.7)	(0.17)	0.0	N/A	N/A
12/17	4.3	(4.6)	(0.14)	0.0	N/A	N/A
12/18e	7.0	(5.6)	(0.09)	0.0	N/A	N/A
12/19e	6.3	(7.3)	(0.19)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

## REIMAGINE trial to test holistic vafidemstat effects

Oryzon successfully initiated a further Phase IIa trial with vafidemstat, a dual LSD1/MAOB inhibitor, in aggression. The innovative trial design (basket trial) has been borrowed from drug development in oncology and will include patients with Lewy body dementia, AD, autism spectrum disorder, borderline personality disorder and attention deficit hyperactivity disorder. Aggression is often seen in a variety of neurodegenerative and neuropsychiatric conditions and vafidemstat has demonstrated holistic effects in this regard in preclinical models (more detailed overview in our recent [outlook report](#)). Oryzon hopes that testing it in different conditions will allow it to pin down a more precise psychiatric setting where the drug could be useful. Preliminary results are expected in H119.

## Two new trials with iadademstat about to start

Oryzon has received authorisation from the regulatory authorities to initiate two Phase IIa studies with iadademstat, a specific LSD1 inhibitor. The Phase IIa ALICE study will recruit elderly AML patients (n=36) who will receive ORY-1001 in combination with standard of care, azacitidine. The other Phase IIa CLEPSIDRA trial will recruit relapsed SCLC patients (n=36) who will receive iadademstat in combination with platinum-etoposide chemotherapy. Interim results from both studies are expected in 2019. We have reviewed key data on iadademstat in our [outlook report](#), including an article recently published in [Cell](#), where a team at the Harvard Medical School described the findings that inhibiting LSD1 could lead to the activation of immune response and overcomes resistance to anti-PD-1 therapy.

## Valuation: €342m or €8.7 per share

At €342m our valuation is marginally higher on an absolute basis and slightly lower on a per-share basis at €8.7/share (from €328m or €9.6/share) due to the share issue and rolling our model forward. Near-term catalysts will be multiple preliminary readouts from the Phase IIa studies in 2019.

9 November 2018

**Price** €3.13

**Market cap** €122m

US\$1.16/€

Net cash (€m) at end Q318 (including share issue in October 2018) 16.3

Shares in issue 39.1m


Free float 65%

Code ORY

Primary exchange Madrid Stock Exchange

Secondary exchange N/A

### Share price performance



% 1m 3m 12m

Abs (19.1) (16.0) 43.8

Rel (local) (19.0) (10.8) 60.3

52-week high/low €5.0 €1.8

### Business description

Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and SCLC; Vafidemstat, its CNS product, is in Phase IIa trials in MS, AD and aggression. Newer asset ORY-3001 is being developed for certain orphan indications.

### Next events

Preliminary readouts from Phase IIa studies with vafidemstat and iadademstat H119

### Analysts

Jonas Peculis +44 (0)20 3077 5728

Alice Nettleton +44 (0)20 3077 5700

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**Oryzon Genomics is a research client of Edison Investment Research Limited**

## Two Phase IIa readouts are key short-term catalysts

The two ongoing lead trials are the Phase IIa ETHERAL and SATEEN studies testing vafidemstat in AD and MS patients respectively.

- ETHERAL trial (n=150) is a randomised, double-blind, placebo-controlled, 24-week study with ORY-2001 in mild-to-moderate AD patients.
- A randomised, double-blind, placebo-controlled, 36-week SATEEN study (n=24) will evaluate vafidemstat in patients with relapsing-remitting MS and secondary progressive MS.


The readouts from these trials are expected in H219 and will provide the first insights into the clinical efficacy of the drug.

### Exhibit 1: R&D pipeline

Product	Indication and stage	Mechanism of action	Notes
Iadademstat (ORY-1001)	<ul style="list-style-type: none"> <li>■ AML, Phase IIa ALICE trial in combination with azacitidine</li> <li>■ SCLC, Phase IIa CLEPSIDRA trial in combination with platinum-etoposide</li> </ul>	Small molecule LSD1 inhibitor - LSD1 is a histone eraser enzyme that removes methyl groups	<ul style="list-style-type: none"> <li>■ Oryzon reported supportive Phase I/IIa data in acute leukaemia at the ASH conference in December 2016.</li> <li>■ Two new Phase IIa trials are about to start enrolling patients in AML (ALICE) and SCLC (CLEPSIDRA). <b>First readouts from both trials expected in Q219.</b></li> </ul>
Vafidemstat (ORY-2001)	<ul style="list-style-type: none"> <li>■ AD, Phase IIa ETHERAL trial, monotherapy</li> <li>■ MS, Phase II SATEEN trial, monotherapy</li> <li>■ Aggression, Phase IIa REIMAGINE trial, monotherapy</li> </ul>	Small molecule LSD1 and MAOB inhibitor	<ul style="list-style-type: none"> <li>■ Reported Phase I safety and PK/PD data from healthy volunteers on 31 March 2017 at the ADPD conference.</li> <li>■ Oryzon initiated clinical trials in MS (SATEEN) and AD (ETHERAL). <b>Preliminary readouts expected in H219.</b></li> <li>■ Basket trial REIMAGINE in aggression in several neuropsychiatric disorders initiated. <b>Preliminary readout expected Q119.</b></li> </ul>
ORY-3001	<ul style="list-style-type: none"> <li>■ Undisclosed non-oncological diseases</li> </ul>	Small molecule LSD1 inhibitor	Initial positive preclinical data published in sickle cell disease, but further development not disclosed yet. Successfully completed regulatory toxicology.

Source: Edison Investment Research, Oryzon Genomics

### Exhibit 2: Expected 2018–2019 newsflow



Source: Oryzon Genomics

## Financials and valuation

According to Oryzon's Q318 report, R&D costs were €1.7m, compared with €1.3m in Q317. We expect R&D costs to increase somewhat in Q418 and FY19 due to the initiation of two new Phase IIa studies, so our estimates remain unchanged (FY18 and FY19 R&D costs of €8.5m and €9.5m respectively). SG&A costs for Q318 were €0.7m, compared with €0.9m in Q317, in line with our expectations.

The private placement transaction closed on 31 October 2018 and raised gross proceeds of €13m at €2.62 per share (12% discount to average of the closing price over the previous three days). The reported Q318 cash position was €22.5m. Considering this cash position, the private placement (post-period) and total debt (€18.4m) bring the estimated net cash to €16.3m. Our model suggests this should be sufficient well into H220.

Our valuation is higher on an absolute basis at €342m and slightly lower on a per-share basis at €8.7 per share (from €328m or €9.6 per share) due to the share issue and rolling our model forward. As Oryzon is on track to develop its assets in all the indications we include in our valuation, we leave our assumptions unchanged. Near-term catalysts will be multiple preliminary readouts from Phase IIa studies in 2019 (Exhibit 1).

**Exhibit 3: Oryzon rNPV valuation**

Product	Indication	Launch	Peak sales (US\$m)	Value (€m)	Probability of success (%)	rNPV (€m)	NPV/share (€/share)
ladademstat (ORY-1001)	AML	2023	927	271.7	15	49.7	1.3
ladademstat (ORY-1001)	SCLC	2026	571	132.9	8	23.0	0.6
Vafidemstat (ORY-2001)	AD	2026	4,510	991.6	15	153.5	3.9
Vafidemstat (ORY-2001)	MS	2027	1,940	438.8	20	104.1	2.7
Net cash (est. end-2018 + share issue)				11.6	100	11.6	0.3
<b>Valuation</b>				<b>1,846.6</b>		<b>341.9</b>	<b>8.7</b>

Source: Edison Investment Research

**Exhibit 4: Financial summary**

	€000s	2016	2017	2018e	2019e
		Local GAAP	Local GAAP	Local GAAP	Local GAAP
December					
<b>PROFIT &amp; LOSS</b>					
Revenue		5,009	4,317	7,034	6,301
Cost of Sales		0	0	0	0
Gross Profit		5,009	4,317	7,034	6,301
Research and development		(5,210)	(5,306)	(8,502)	(9,454)
EBITDA		(3,721)	(3,498)	(4,678)	(6,350)
Operating Profit (before amort. and except.)		(3,879)	(3,660)	(3,879)	(3,660)
Intangible Amortisation		(695)	(664)	(767)	(887)
Exceptionals		(4)	0	0	0
Other		0	0	0	0
Operating Profit		(4,578)	(4,324)	(5,556)	(7,348)
Exceptionals		(58)	0	0	0
Net Interest		(844)	(928)	(793)	(802)
Profit Before Tax (norm)		(4,724)	(4,588)	(5,582)	(7,263)
Profit Before Tax (reported)		(5,480)	(5,252)	(6,349)	(8,150)
Tax		32	55	2,200	0
Profit After Tax (norm)		(4,692)	(4,533)	(3,382)	(7,263)
Profit After Tax (reported)		(5,448)	(5,197)	(4,149)	(8,150)
Average Number of Shares Outstanding (m)		27.6	27.6	31.7	36.6
EPS - normalised (c)		(0.17)	(0.14)	(0.09)	(0.19)
EPS - reported (EUR)		(0.20)	(0.16)	(0.11)	(0.21)
Dividend per share (c)		0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	100.0	100.0	100.0
EBITDA Margin (%)		N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	N/A
<b>BALANCE SHEET</b>					
Fixed Assets		21,269	24,914	31,070	36,373
Intangible Assets		18,810	22,458	28,725	34,139
Tangible Assets		696	638	527	417
Investments		1,763	1,818	1,818	1,818
Current Assets		28,475	36,130	33,640	13,993
Stocks		8	7	150	79
Debtors		978	857	3,500	2,178
Cash		22,028	34,950	29,990	11,736
Other		5,461	316	0	0
Current Liabilities		(7,597)	(8,696)	(10,084)	(3,890)
Creditors		(2,119)	(1,343)	(1,731)	(1,537)
Short term borrowings		(5,477)	(7,354)	(8,354)	(2,354)
Long Term Liabilities		(19,419)	(17,915)	(11,992)	(11,992)
Long term borrowings		(17,723)	(16,041)	(10,041)	(10,041)
Other long term liabilities		(1,696)	(1,874)	(1,951)	(1,951)
Net Assets		22,729	34,432	42,633	34,483
<b>CASH FLOW</b>					
Operating Cash Flow		(4,536)	(4,281)	(7,792)	(5,953)
Net Interest		(471)	(426)	(793)	(802)
Tax		0	0	2,200	0
Capex		(28)	(105)	0	0
Acquisitions/disposals		0	0	0	0
Financing		287	16,887	12,350	0
Other*		(6,819)	653	(5,925)	(5,499)
Dividends		0	0	0	0
Net Cash Flow		(11,567)	12,728	40	(12,254)
Opening net debt/(cash)		(10,395)	1,172	(11,555)	(11,595)
HP finance leases initiated		0	0	0	0
Other		0	0	(0)	0
Closing net debt/(cash)		1,172	(11,555)	(11,595)	659

Source: Edison Investment Research, Oryzon Genomics accounts. Note: Oryzon reports in Spanish GAAP. \*Includes cash outflows related to development costs that were capitalised.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Oryzon Genomics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and the fore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.